​

Reglan Tardive Dyskinesia Settlement: Statute of Limitations for Reglan in Arizona

From General Health Information to Specific Exposure Risk

For decades, general health and science information has served as the foundation for public understanding of medication risks and patient safety. This broad educational context has empowered individuals to recognize potential adverse effects associated with prescription drugs, including those used in gastrointestinal and neurological care. Within this legacy framework, the focus has remained on informing patients about possible side effects without delving into specific disease mechanisms or clinical pathways. As this general awareness evolves, a more targeted concern has emerged in occupational and clinical settings: the prolonged use of Reglan (metoclopramide) and its association with tardive dyskinesia. This movement disorder, characterized by involuntary muscle movements, has become a significant focus for individuals who have been exposed to the medication over extended periods. The transition from broad health education to specific exposure risk is particularly relevant in states like Arizona, where legal considerations such as statutes of limitations now intersect with patient experiences. This shift in perspective moves the conversation from general health literacy to a practical, exposure-based concern. For those who have taken Reglan for conditions like gastroparesis or reflux, the risk of tardive dyskinesia represents a tangible outcome that may require legal and medical attention. The legacy of general health information thus provides the necessary backdrop for understanding this more focused occupational and clinical exposure issue.

Understanding Reglan and Tardive Dyskinesia

Reglan (metoclopramide) is a medication approved for short-term use in adults with symptomatic gastroesophageal reflux or diabetic gastroparesis, but its association with tardive dyskinesia (TD) carries significant medical and legal implications. The FDA-approved labeling includes a boxed warning stating that metoclopramide, including Reglan, can cause TD, a potentially irreversible serious movement disorder (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The risk of developing TD increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan is contraindicated in patients with a history of TD, and healthcare providers are instructed to use the drug for the shortest duration necessary, with periodic reassessment of continued need (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients with symptomatic gastroesophageal reflux, the maximum approved treatment duration is 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). In diabetic gastroparesis, total treatment duration should also be limited to 12 weeks, though longer use may be unavoidable in some cases, requiring routine monitoring for TD signs and symptoms (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Tardive dyskinesia is characterized by potentially irreversible and disfiguring involuntary movements of the face or tongue, and sometimes the trunk or extremities (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The condition may be partially suppressed by metoclopramide itself, which can delay diagnosis by masking underlying disease processes (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The mechanistic pathway involves chronic dopamine receptor blockade in the basal ganglia, leading to supersensitivity and abnormal involuntary movements. Reglan is not recommended for pediatric patients due to the risk of TD and other extrapyramidal symptoms, as well as methemoglobinemia in neonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

​

Legal Considerations and Statute of Limitations in Arizona

From a risk perspective, the adequacy of warnings regarding Reglan and TD is a central issue. The boxed warning clearly states the risk, but questions arise about whether prescribers and patients were adequately informed, especially given that many patients used Reglan for extended periods beyond the recommended 12-week limit. The warning advises immediate discontinuation of Reglan if signs or symptoms of TD develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, the insidious onset of TD and its potential masking by the drug itself complicate timely recognition. For affected patients in Arizona, settlement-related considerations depend on the statute of limitations, which governs the time window to file a claim. In Arizona, personal injury claims generally must be filed within two years from the date the injury is discovered or reasonably should have been discovered. For TD, this discovery date may be when a patient first notices abnormal movements or receives a formal diagnosis. The timeline between Reglan exposure and documented harm is critical: TD can develop after months or years of use, and symptoms may persist or worsen even after discontinuation. Patients who used Reglan for longer than 12 weeks, or who were not monitored for TD, may have stronger claims regarding inadequate warnings or failure to limit treatment duration. Settlement amounts in Reglan TD cases often reflect factors such as the severity of TD symptoms, duration of Reglan use, presence of adequate warnings, and the patient's age and overall health. In Arizona, courts may consider whether the manufacturer provided sufficient risk information to prescribers and patients. The boxed warning explicitly states that risk increases with treatment duration and cumulative dose, and that Reglan should be used for the shortest time possible (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). If a patient was prescribed Reglan for longer than 12 weeks without documented reassessment, this may support a claim of inadequate monitoring or failure to heed labeling guidance. Patients seeking settlement should gather medical records documenting Reglan prescriptions, duration of use, and any TD diagnosis. Legal counsel can assess whether the statute of limitations has been met, considering the date of TD discovery. Given the potentially irreversible nature of TD, early legal consultation is advisable to preserve claims. The FDA labeling emphasizes that Reglan is not indicated for long-term use, and that TD can occur even after short-term exposure, though risk is higher with prolonged therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). In Arizona, the two-year statute of limitations for personal injury claims applies, but exceptions may exist for delayed discovery. Patients should act promptly to avoid losing their right to seek compensation.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Take the first step toward compensation.

Do not fill

We connect historical research with modern accountability. Submitting this form does not immediately create an attorney-client relationship. Urgent medical issues require emergency services.

By clicking the button below, I expressly consent to be contacted by the operator of this website and one legal intake partner matched to my inquiry via phone calls, emails, and/or text messages at the number provided. I understand that this contact may include the use of an automated telephone dialing system (ATDS) or artificial/prerecorded voices. I acknowledge that my consent is not a condition of purchasing any goods or services, and I can revoke it at any time. Request Claim Assessment

Frequently Asked Questions

What is the statute of limitations for Reglan-related tardive dyskinesia claims in Arizona?

In Arizona, personal injury claims generally must be filed within two years from the date the injury is discovered or reasonably should have been discovered. For tardive dyskinesia, this discovery date may be when a patient first notices abnormal movements or receives a formal diagnosis. Exceptions may exist for delayed discovery, so prompt legal consultation is advised.

How does the duration of Reglan use affect a tardive dyskinesia claim?

The risk of developing tardive dyskinesia increases with duration of treatment and total cumulative dosage. The FDA boxed warning states that Reglan should be used for the shortest duration necessary, with a maximum of 12 weeks for most indications. Patients who used Reglan for longer than 12 weeks without documented reassessment may have stronger claims regarding inadequate monitoring or failure to heed labeling guidance.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Related Articles

• Illinois Reglan Tardive Dyskinesia injury lawyer
• Florida Reglan Tardive Dyskinesia injury lawyer
• Statute of limitations for Reglan in California
• Reglan linked to Tardive Dyskinesia
• Statute of limitations for Reglan in Texas

References

1. DailyMed - Reglan Labeling

Request a Free Case Review

Begin Assessment

Submitting requests an initial records screening only and does not create an attorney-client relationship.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.